Loading organizations...
Immutrin, based in Cambridge, UK, develops next-generation antibody therapies designed to reverse ATTR amyloidosis by activating the body's natural defense mechanisms to remove amyloid deposits from tissues. The biotechnology company's approach builds on decades of research and antibody expertise, primarily targeting ATTR cardiomyopathy. Immutrin recently raised £65 million ($87 million) in Series A financing led by Frazier Life Sciences, with participation from F-Prime, Qiming Venture Partners, SR One, and Cambridge Innovation Capital. This funding, overseen by CEO Mihriban Tuna and Chair Sef Kurstjens, will advance proof-of-concept clinical trials for their lead therapeutic candidate. The organization was founded around 2019 by Professor Sir Mark Pepys FRS, Nobel Laureate Sir Gregory Winter FRS, Professor Daniel Christ, and Cambridge Innovation Capital. Its business model centers on biotechnology company funded by venture capital investments, including a recent Series A round.
Immutrin has raised $87.0M across 1 funding round.
Immutrin has raised $87.0M in total across 1 funding round.
Immutrin has raised $87.0M across 1 funding round. Most recently, it raised $87.0M Series A in March 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2026 | $87M Series A | Frazier Life Sciences, James Topper, Frazier Lifesciences Acquisition Corporation | Cambridge Enterprise, Mihriban Tuna, Nihal Sinha, Alexander Sinclair Wilson, SR ONE | Announced |
Immutrin has raised $87.0M in total across 1 funding round.
Immutrin's investors include Frazier Life Sciences, James Topper, Cambridge Enterprise, Mihriban Tuna, Nihal Sinha, Alexander Sinclair Wilson, SR One.
